ATE74512T1 - Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. - Google Patents
Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.Info
- Publication number
- ATE74512T1 ATE74512T1 AT87115694T AT87115694T ATE74512T1 AT E74512 T1 ATE74512 T1 AT E74512T1 AT 87115694 T AT87115694 T AT 87115694T AT 87115694 T AT87115694 T AT 87115694T AT E74512 T1 ATE74512 T1 AT E74512T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- recombinant interleukin
- manufacture
- solubilizer
- stabilizers
- Prior art date
Links
- 102000000588 Interleukin-2 Human genes 0.000 title abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92338386A | 1986-10-27 | 1986-10-27 | |
| EP87115694A EP0268110B1 (de) | 1986-10-27 | 1987-10-26 | Pharmazeutische Zusammensetzungen von rekombinanten Interleukin-2 und Herstellungsverfahren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE74512T1 true ATE74512T1 (de) | 1992-04-15 |
Family
ID=25448603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT87115694T ATE74512T1 (de) | 1986-10-27 | 1987-10-26 | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0268110B1 (de) |
| JP (1) | JPS63122628A (de) |
| AT (1) | ATE74512T1 (de) |
| AU (1) | AU614066B2 (de) |
| CA (1) | CA1292686C (de) |
| DE (1) | DE3778122D1 (de) |
| ES (1) | ES2036558T3 (de) |
| GR (1) | GR3004479T3 (de) |
| IE (1) | IE60890B1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
| US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US6054441A (en) * | 1987-10-28 | 2000-04-25 | Pro-Neuron, Inc. | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis |
| KR910700061A (ko) * | 1988-12-06 | 1991-03-13 | 오스카 아끼히꼬 | 인터로이킨-1β의 안정화 조성물 |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
| JPH0791318B2 (ja) * | 1989-09-21 | 1995-10-04 | 三井東圧化学株式会社 | 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤 |
| US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| CZ290342B6 (cs) * | 1992-10-02 | 2002-07-17 | Genetics Institute Inc. | Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby |
| CA2147466A1 (en) * | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| CA2463655A1 (en) | 2001-10-15 | 2003-04-24 | Chiron Corporation | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| ATE474599T1 (de) | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom |
| PT1684869E (pt) | 2003-11-04 | 2011-09-16 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros relacionados com células b |
| PT1680141E (pt) | 2003-11-04 | 2010-12-20 | Novartis Vaccines & Diagnostic | Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40 |
| AU2004287480B2 (en) | 2003-11-04 | 2011-09-15 | Novartis Vaccines And Diagnostics, Inc. | Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia |
| PT1694360E (pt) | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
| GB0404586D0 (en) * | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
| JP5518608B2 (ja) * | 2010-07-09 | 2014-06-11 | ロート製薬株式会社 | 粘膜適用液状組成物 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| AU2011335551B2 (en) | 2010-12-02 | 2016-10-06 | Bionor Immuno As | Peptide scaffold design |
| CA2821995C (en) | 2011-01-06 | 2019-02-12 | Bionor Immuno As | Monomeric and multimeric peptides immunogenic against hiv |
| DE102012101864A1 (de) * | 2012-03-06 | 2013-09-12 | Gramme-Revit Gmbh | Mittel zur Behandlung von Allergien und anderen Erkrankungen |
| WO2013182661A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| EP3718467A1 (de) | 2013-04-23 | 2020-10-07 | Cedars-Sinai Medical Center | Systeme und verfahren zur gleichzeitigen aufzeichnung eines bildes im sichtbaren licht und infrarotlicht aus fluorophoren |
| CA2935404A1 (en) | 2014-01-17 | 2015-07-23 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| US10029997B2 (en) | 2014-06-12 | 2018-07-24 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
| US11786469B2 (en) | 2014-07-22 | 2023-10-17 | Cheolhee WON | Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome |
| EP3215186A4 (de) | 2014-11-04 | 2018-10-24 | University of Southern California | Zusammensetzungen und verfahren zur behandlung von hif-1 alpha-überexprimierenden karzinomen |
| AU2016258984B2 (en) | 2015-05-05 | 2020-11-19 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| EP3345000B1 (de) | 2015-08-31 | 2022-08-31 | Cedars-Sinai Medical Center | Neuartige blutzellenbiomarker für spät einsetzendem morbus alzheimer |
| KR20180103817A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
| CA3052561C (en) | 2017-02-06 | 2023-02-14 | Lemonex Inc. | Physiologically active substance carrier |
| WO2018143787A1 (ko) | 2017-02-06 | 2018-08-09 | 주식회사 레모넥스 | 생리활성물질 전달체 |
| EP3658139A4 (de) | 2017-07-25 | 2021-04-07 | Cedars-Sinai Medical Center | Verfahren zur behandlung von lebererkrankungen |
| AU2018321950A1 (en) | 2017-08-22 | 2020-03-19 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
| US11530132B2 (en) | 2017-09-05 | 2022-12-20 | Lemonex Inc. | Composition comprising porous silica particles carrying a cell fate modulating factor |
| EP3877412A4 (de) | 2018-11-08 | 2022-08-10 | Cedars-Sinai Medical Center | Verwendung von clazakizumab zur desensibilisierung und verbesserung der nierentransplantation bei hla-sensitiven patienten |
| US20220073605A1 (en) | 2018-12-20 | 2022-03-10 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| CA3201446A1 (en) * | 2020-11-13 | 2022-05-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2652636A1 (de) * | 1976-11-19 | 1978-05-24 | Hans Uwe Dr Rer Nat Wolf | Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung |
| US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| JPS61500790A (ja) * | 1984-03-28 | 1986-04-24 | シタス コ−ポレイシヨン | 微生物的に製造されたインターロイキン―２を含有する組成物 |
| EP0158487B1 (de) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stabile Interleukin-2-Zusammensetzung |
| CA1297003C (en) * | 1985-09-20 | 1992-03-10 | Jack H. Nunberg | Composition and method for treating animals |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
-
1987
- 1987-10-16 CA CA000549488A patent/CA1292686C/en not_active Expired - Lifetime
- 1987-10-22 IE IE284487A patent/IE60890B1/en not_active IP Right Cessation
- 1987-10-26 EP EP87115694A patent/EP0268110B1/de not_active Expired - Lifetime
- 1987-10-26 AT AT87115694T patent/ATE74512T1/de not_active IP Right Cessation
- 1987-10-26 ES ES198787115694T patent/ES2036558T3/es not_active Expired - Lifetime
- 1987-10-26 DE DE8787115694T patent/DE3778122D1/de not_active Expired - Lifetime
- 1987-10-27 JP JP62271603A patent/JPS63122628A/ja active Pending
- 1987-10-27 AU AU80181/87A patent/AU614066B2/en not_active Expired - Fee Related
-
1992
- 1992-05-04 GR GR920400417T patent/GR3004479T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3778122D1 (de) | 1992-05-14 |
| EP0268110A1 (de) | 1988-05-25 |
| AU8018187A (en) | 1988-04-28 |
| JPS63122628A (ja) | 1988-05-26 |
| CA1292686C (en) | 1991-12-03 |
| IE60890B1 (en) | 1994-08-24 |
| ES2036558T3 (es) | 1993-06-01 |
| IE872844L (en) | 1988-04-27 |
| EP0268110B1 (de) | 1992-04-08 |
| AU614066B2 (en) | 1991-08-22 |
| GR3004479T3 (de) | 1993-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE74512T1 (de) | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. | |
| ATE111744T1 (de) | Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren. | |
| DK0388220T3 (da) | Præparater til vedvarende frigivelse af klorhexidin | |
| FI905956A0 (fi) | Foerfarande foer producering av ett biologiskt aktivt protein. | |
| AU590896B2 (en) | Improved formulations for recombinant beta-interferon | |
| DK16890D0 (da) | Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf | |
| ATE72988T1 (de) | Fettsaeure-zusammensetzungen. | |
| DE3681243D1 (de) | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. | |
| DK0693924T3 (da) | Fremgangsmåde til (in vivo)-levering af biologiske materialer og sammensætninger, der er egnede dertil | |
| IT1232827B (it) | Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle | |
| SE8404065D0 (sv) | Novel biologically active compounds | |
| FR2707638B1 (fr) | Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique. | |
| IT1240683B (it) | Composizione farmaceutica contenente egf | |
| ATE85213T1 (de) | Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel. | |
| DK291390A (da) | Terapeutiske anvendelser af 2',5'-oligoadenylatderivater | |
| ATE175213T1 (de) | Ch0ndromodulin-ii protein | |
| FR2605223B1 (fr) | Compositions therapeutiques stables a base d' huile vegetale hydrophobe et son procede de preparation | |
| DE3781017D1 (de) | Cytotoxische zusammensetzung aus "killer"-zellen. | |
| IT1197892B (it) | Composizioni farmaceutiche ad attivita' cicatrizzante | |
| BG60657B2 (en) | Human recombinant interleukin-2 muteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEFA | Change of the company name | ||
| EEIH | Change in the person of patent owner | ||
| EELA | Cancelled due to lapse of time |